The Drug Supply Chain Security Act (DSCSA) is one of the two titles that comprises DQSA and it creates a uniform, national standard for tracing drug products through the supply chain. The goal of DQSA is to enhance FDA's ability to help protect consumers by detecting and removing potential dangerous products from the pharmaceutics distribution supply chain. DQSA outlines all the steps of a new electronic, interoperable system that will identify and trace certain prescription medication while distributed in the United States. The development of this system will be phased in with specific requirements over a 10 year period. It will be a cooperation between FDA and drug manufactures, wholesale drug distributors, repackagers and dispensers (primarily pharmacies).
3 Table 1 . outlines all the services that the DQSA's new system will provide.
The implementation of the DSCSA is based on several law requirements and FDA has developed a schedule with time frames for each of them to be executed over a 10 year period. There are 15 key activities of the FDA plan that will guarantee an efficient and effective implementation described in table 2. 4 Moreover, there are certain key provisions of the DSCSA which will be implemented over the next 10 years that require:
I. Product identification: Manufacturers and repackagers to put a unique product identifier on certain prescription drug packages, for example, using a bar code that can be easily read electronically.
II.
Product tracing: Manufacturers, wholesaler drug distributors, repackagers, and many dispensers (primarily pharmacies) in the drug supply chain to provide information about a drug and who handled it each time it is sold in the U.S. market.
III.
Product verification: Manufacturers, wholesaler drug distributors, repackagers, and many dispensers (primarily pharmacies) to establish systems and processes to be able to verify the product identifier on certain prescription drug packages.
IV.
Detection and response: Manufacturers, wholesaler drug distributors, repackagers, and many dispensers (primarily pharmacies) to quarantine and promptly investigate a drug that has been identified as suspect, meaning that it may be counterfeit, unapproved, or potentially dangerous.
V.

Notification:
Manufacturers, wholesaler drug distributors, repackagers, and many dispensers (primarily pharmacies) to establish systems and processes to notify FDA and other stakeholders if an illegitimate drug is found.
VI.
Wholesaler licensing: Wholesale drug distributors to report their licensing status and contact information to FDA. This information will then be made available in a public database.
VII.
Third-party logistics provider licensing: Third-party logistic providers, those who provide storage and logistical operations related to drug distribution, to obtain a state or federal license. In addition, the DSCSA implementation plan includes some important dates for the authorized partners requirements described in the Table 3 . 4 The DSCSA traceability process includes only prescription drugs in the finished form for human use. There are certain products that are excluded from the DSCSA list. Table 4 includes all these products. All sellers must provide the TI, TH, and TS to the subsequent owner for each transaction and each buyer must store the information received. All trading partners must store the records for a period of 6 years and make them available to a FDA audit. 2 Most of the data is stored through web-based portals. There are some changes regarding the dispenser (primarily pharmacies) where the lot number, transaction date and shipment date are required only if the pharmacy purchase a product from a second distributor instead of the primary distributor that buys directly from a manufacturer. In addition, the dispenser can return saleable products or nonsaleable products to the trading partners without providing the requisite information; however by 2019 wholesale distributors will accept return products only if they contain the required product identifier. 2 Tracing exceptions comprises another important feature of the DSCSA that are presented as following:
• In order to help trading partners, FDA has issued a document, FDA Guidance on Identifying Suspect Product and Notification that provides information about the risk of suspect drugs entering the supply chain. Some example scenarios include product sourcing, supply, demand, history, and value of the product, and product appearance. When dealing with product sourcing trading partners should be careful when they purchase from a new and unknown source, receive products from an unknown source, or purchasing from a trading partner who is involved in selling or delivering illegitimate products. In addition, the trading partner has a history of potentially false transaction histories (misspelled words or incomplete information), is reluctant to provide TH, or a TI, TS, and /or TH appears to be suspicious. Another scenario provided in the FDA guidance document is related to supply, demand, history, and value of the product. They include products that are in high demand, have a high sales volume, and have been previously counterfeited. Also, products that have been or are currently the subject of drug shortage, have been subject of illegitimate product notification, and have been the subject of an FDA counterfeit or cargo theft alert. The last FDA example scenario recommends additional caution to a product appearance. Suspicious appearance includes: a transport container with a non-standard label (color, font, images), drug identification number that is different from NDC, missing information (lot number or expiration date), missing counterfeit technologies (holograms, color shifting inks, or watermarks), and a finished product that has different shape or color, unusual imprint or odor, and chips or cracks in the tablet coatings. 6 The scenarios described above should not be view as an exhaustive list of all potential scenarios, but pharmacists and pharmacy technicians can use them to identify suspect products being delivered to their pharmacy. Accessing the DSCSA online resources on the FDA website is another way for dispensers to be up-to date with the implementation plan requirements.
Implementing the DSCSA law requirements is a challenging and complicated process. In order to receive valuable feedback from stakeholders, FDA held a public workshop on "Proposed Pilot Project under the Drug Supply Chain Security Act" in Silver Spring, MD, on April 5-6, 2016. Many participants including drug manufacturers, repackagers, wholesale distributors, third-party logistics providers, dispensers (pharmacies), and consultants shared their input related to the product identifiers, barcodes, interoperability, aggregation, database issues, and verification and notification issues. Moreover, the implementation of DSCSA requirements are not cheap, some of them include costs of $150-300,000 per packaging line and installation of IT systems to store and transmit data just to name a few. 2 I believe that a unified system will provide easier data exchange and fewer errors, will increase the safety and security of the pharmaceutical distribution supply chain. In addition, it will improve the supply-demand balance, allow better control of inventory, facilitate easier returns and recalls, decrease drug diversion and uncontrolled pricing.
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